Premium
Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature
Author(s) -
Visentin Andrea,
Imbergamo Silvia,
Trimarco Valentina,
Pravato Stefano,
Romano Gargarella Leila,
Frezzato Federica,
Scapinello Greta,
Bertorelle Roberta,
Piva Elisa,
Facco Monica,
Semenzato Gianpietro,
Piazza Francesco,
Trentin Livio
Publication year - 2020
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2810
Subject(s) - ibrutinib , medicine , oncology , adverse effect , venetoclax , hairy cell leukemia , leukemia , drug , complete remission , chemotherapy , pharmacology , chronic lymphocytic leukemia
Abstract Hairy cell leukemia variant (HCLv) is a provisional disease in the 2016 WHO classification of lymphomas, characterized by unfavorable prognosis and early relapse following conventional purine analog‐based regimens. In this study, we report 2 patients with relapsed HCLv treated with ibrutinib. The first patient achieved a partial response following ibrutinib treatment and received the drug for 16 months, without severe adverse events. However, at disease progression venetoclax was not clinically active. The second patient discontinued the drug early due to intolerance. Ibrutinib was active in our patients with HCLv and deserve further investigations.